Qynapse

Merci France Alzheimer pour #Memorun2024 #WorldAlzheimersDay Qynapse

#ESNR2024 here we are ! Meet our team at ESNR on booth n°15 to present our neuro post processing solution QyScore 🧠 Looking forward to seeing you there 👋 Serge Barbe Olivier Courrèges Aline Fieck Hanthony Biancotto

#ESNR2024 starts today; Meet our team at this year edition of the ESNR on booth n°15 to present our neuro post-processing solution QyScore 🧠 🗓️ September 18-22, 2024 📍 Paris Marriott Rive Gauche Hotel & Conference Center, Paris, France 🤝 Book a demonstration with our team https://lnkd.in/eMiqbKjx Looking forward to see you there !

#ESNR2024 Meet our team at this year edition of the ESNR on booth n°15 to present our neuro post-processing solution QyScore! 🧠 🗓️ September 18-22, 2024 📍 Paris Marriott Rive Gauche Hotel & Conference Center, Paris, France Our upcoming version of QyScore® includes multiple new features to support improvements in the monitoring of efficacy and safety of these new anti-amyloid treatments to maximize the quality of life of patients and their loved ones. ➡ Book a demonstration with our team ! https://lnkd.in/eMiqbKjx We look forward to meeting you to discuss the exciting possibilities ahead !

#ESNR2024 Meet our team at this year edition of the ESNR on booth n°15 to present our neuro post-processing solution QyScore®!  🗓️ September 18-22, 2024 📍 Paris Marriott Rive Gauche Hotel & Conference Center, Paris, France   🧠 As an AI neuroimaging company committed to improving assessment and monitoring of CNS disorders, Qynapse has a well-established history of collaborating with pharmaceutical companies, clinicians and caregivers to enhance patient care.     🔜 Our upcoming version of QyScore® includes multiple new features to support improvements in the monitoring of efficacy and safety of these new anti-amyloid treatments to maximize the quality of life of patients and their loved ones. We look forward to meeting you to discuss the exciting possibilities ahead !   #Neuroradiology #MRI #BrainTumor #Radiology #Congress  Olivier Courrèges Serge Barbe Hanthony Biancotto Yasmine HEDEYA Aline Fieck

New data from a phase 2b/3 study of patients with early-stage #AD showed that treatment with blarcamesine was safe, with no associated neuroimaging adverse events, and resulted in significant slowed clinical decline on several notable end points. Anavex Life Sciences https://lnkd.in/eMgRWU4p

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and noassociated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups Benefits of blarcamesine on both amyloid-beta and brainvolume, two underlying pathological hallmarks of Alzheimer’s disease EMA submission expected in Q4 https://lnkd.in/eX_zYZ7k #anavex #biopharma #neuroscience #precisionmedicine

Join Qynapse at #AAIC24 ! Positive reduction in #QyScore® atrophy measures in an early Alzheimer’s disease population. Qynapse is attending #AAIC24 in Philadelphia and we are looking forward to seeing many of you there for some groundbreaking top line results and new developments to explore. Qynapse are proud to announce their QyScore® quantitative imaging assessment contribution to one such landmark study of Anavex Life Sciences’s #Blarcamesine (ANAVEX2-73) Phase IIb/III trial in an early Alzheimer’s disease population. The clinical and imaging results will be presented by Professor Marwan Sabbagh on the first day of the conference, today, Sunday 28th July. Definitely not to be missed! Qynapse’s team, including our VP of Medical Imaging, Dr. Elizabeth Gordon and our CEO Olivier Courrèges are attending in person to discuss their expanding capabilities in clinical trials across CNS and these exciting topline results, which demonstrated a significant and measurable slowing of atrophy in patients on oral Blarcamesine using their fully automated quantitative certified QyScore® pipelines. Our clinical sciences team will also be presenting two posters: Poster Number: Monday-400 and Tuesday-485 exploring our QyScore® and QyPredict® prognostic tool performances.

Yesterday's announcement of the FDA’s approval of Eli Lilly and Company's Donanemab (Kisunla) highlights a major milestone in the fight against Alzheimer’s disease. Alongside Eisai Co., Ltd./Biogen’s Lecanemab (Leqembi), these new therapies offer hope and real treatment options to millions of patients. As an AI neuroimaging company committed to improving assessment and monitoring of CNS disorders, Qynapse has a well-established history of collaborating with pharmaceutical companies, clinicians and caregivers to enhance patient care. Our upcoming version of QyScore® includes multiple new features to support improvements in the monitoring of efficacy and safety of these new anti-amyloid treatments to maximize the quality of life of patients and their loved ones. We look forward to meeting you at #AAIC2024 to discuss the exciting possibilities ahead. Olivier Courrèges Elizabeth Gordon

🌟 Exciting Alert: Qynapse announces a global commercial partnership with EDL 🌟 We are proud to announce that EDL has partnered with Qynapse, integrating QyScore strengths into the innovative XPlore AI system. Our shared goal? Enhancing clinician experiences with our AI-powered automatic image analysis engine QyScore for the diagnosis and follow-up of CNS diseases. This collaboration leverages EDL's robust and proven workflow expertise, aligning perfectly with Qynapse’s global strategy to expand across Europe. This partnership is set to revolutionize how clinicians utilize our latest biomarkers, advancing precision medicine and improving patient outcomes. Interested in learning more? Join EDL's team at Santexpo starting tomorrow. See how we're driving the future of healthcare together! Yannick Ré Mélanie Canin Olivier Courrèges Hanthony Biancotto